Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?
Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?
ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.
Why FDA’s clearance of ACON’s Flowflex Plus test marks a turning point in home diagnostics
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.